Bosnia and Herzegovina: data sheet

Bosnia and Herzegovina: about the data presented on this page

Bosnia and Herzegovina does not have a national drug observatory (NDO), and thus has a limited capacity to carry out studies and establish a national drug information system. The EUDA-IPA national correspondent is based at the Ministry of Security and has limited access to data on health.

The data presented here are reported to the EUDA by the national correspondent on an annual basis and should conform to the respective EUDA guidelines and protocols. Details on methods and definitions can be found in the EUDA Statistical Bulletin.

Prevalence and patterns of drug use

Drug use in the adult population

The most recent general population survey in Bosnia and Herzegovina was conducted in 2018 with the financial support of the IPA6 project. The situation in Bosnia and Herzegovina may have changed since 2018 and the data should therefore be interpreted with caution. The complete report can be downloaded from our Document library.

Drug use in the school population

Information about drug use in the school population is available from the series of ESPAD surveys among 15- to 16-year-old students. The most recent survey was conducted in Bosnia and Herzegovina in 2011. Data are available separately for the entities, Republika Srpska and Federation of Bosnia and Herzegovina.

European Web Survey on Drugs

Bosnia and Herzegovina participated in the 2024 round of the European Web Survey on Drugs (EWSD); data will be available soon. Although web surveys are not representative of the general population, when they are carefully conducted and combined with traditional data collection methods, they can help paint a more detailed, realistic and timely picture of drug use and drug markets in Europe and the European neighbourhood. As such, they are a key ingredient in the EUDA responsiveness to an ever-shifting drug problem.

More information is available on the EWSD topic hub page.

High-risk drug use

There have been no recent studies conducted in Bosnia and Herzegovina to estimate the size of the high-risk drug using population. A 2012 estimate of 12,500 people who use opioids or inject drugs is sometimes mentioned by experts, but is likely outdated, and the source of the data is not known.

Drug-related harms

Infectious diseases

The monitoring of drug-related infectious diseases among people who inject drugs (PWID) in Bosnia and Herzegovina historically relied on bio-behavioural surveys supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria. No such survey has been conducted since 2015. Data on incidence (new cases attributed to injecting drug use) are available, but only information on HIV is reported to the European Centre for Disease Prevention and Control (ECDC).

Hospital emergencies

Data on hospital emergency presentations can provide a unique insight into acute health harms related to drug use. Euro-DEN Plus uses a sentinel centre model to collect data on emergency department presentations with acute drug toxicity. While the data do not necessarily provide a nationally representative picture, as only selected sites are included from participating countries, using a number of sentinel sites in significant locations provides useful information on the types of drug involved in presentations to emergency services, and the trends at these sites. Data are not yet available for Bosnia and Herzegovina.

Drug-induced deaths

Data on drug-induced deaths are not currently available from Bosnia and Herzegovina.

Responses

Treatment provision

Bosnia and Herzegovina does not have a national register for specialised drug treatment, and data on people entering treatment are not available.

Opioid agonist treatment

Data on the provision of opioid agonist treatment (OAT) in Bosnia and Herzegovina are not available.

Harm reduction provision

Bosnia and Herzegovina does not have any needle and syringe programmes and has reported zero sterile syringes distributed per year since the beginning of the routine reporting to the EUDA in 2020.

Drug markets and crime

Drug law offences

This security indicator collects information on the number of offences or offenders/suspected offenders by type of offence and substance, and describes the characteristics and trends of drug law offences, criminal and non-criminal. The collection of data may be challenging since it can be collected at different stages in the criminal justice system from different sources (e.g. from initial reports submitted by the police, cases of criminal offences submitted to the prosecutor) and information systems on drug law offences and offenders vary considerably between countries, especially as regards recording procedures, definitions and statistical units.

Drug seizures

This security indicator describes the characteristics and trends of drug seizures in order to improve our understanding of drug markets and supply-reduction activities. Data on drug seizures relate to all seizures during the year by all law enforcement agencies, mainly police and customs. All trend data, though, are subject to extraneous influences, such as changes in legislation, changes in police practices. There are no cases of double-counting between various agencies.

Purity/potency

This security indicator collects drug purity/potency data for some illicit substances including cannabis products, opioids and stimulants. The potency of cannabis products is defined as the delta-9-tetrahydrocannabinol (THC) content, where THC is the primary psychoactive constituent in cannabis. It is expressed in percent of THC. The laboratories and forensic science institutes undertaking quantitative drug determinations for law enforcement are the primary source of information. These facilities collect and register drug purity/potency data and related information.

Drug prices

This security indicator collects data on the prices of all types of drugs at retail, middle-market and wholesale levels. Street prices of cannabis, heroin, cocaine and amphetamine are provided in euro per gram, LSD in euro per unit/dose and MDMA/ecstasy in euro per tablet. Data on prices come from a range of different sources, the comparability of which is not always known.

Links to other sources of information

Relevant EMCDDA/EUDA publications

• EMCDDA trendspotter briefing – Illicit drug markets and supply in the Western Balkans: Impact of COVID-19
• EMCDDA trendspotter briefing: Impact of COVID-19 on drug use and drug services in Western Balkans
• Drug treatment systems in the Western Balkans: outcomes of a joint EMCDDA-UNODC survey of drug treatment facilities
• Drug use and its consequences in the Western Balkans 2006–14
• Drug-related health and security threats in the Western Balkans

External data sources

• ECDC: HIV/AIDS surveillance in Europe 2023, 2022 data
• dataUNODC: UNODC data on several topics, including drugs trafficking and production and drug use and treatment
• UNODC Drugs Monitoring Platform: data on drug trafficking trends and on individual drugs seizures (IDS) dataset, which contains information on singular interception or apprehension

Source data

The data used to generate the infographics and charts on this page may be found below (CSV format). Additional information. metadata and methodological notes may be found in the IPA country data sheets background tables and source data entry in our Data catalogue.

Show source tables